Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Gemcitabine

Review the clinical trials studying gemcitabine on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 101-125 of 134

Partial Cystectomy and Extended Pelvic Lymph Node Dissection with Standard of Care Systemic Therapy for the Treatment of Muscle-Invasive Bladder Cancer
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Circulating Tumor DNA to Determine Early Switch From First-Line mFOLFIRINOX to Second-Line Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) cells with or without Naxitamab (Danyelza) for the Treatment of Patients with Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies
Status: Active
Location: 3 locations
CTX-009, Gemcitabine, Cisplatin, and Durvalumab for the Treatment of Patients with Unresectable, Metastatic, or Recurrent Biliary Tract Cancers
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Status: Active
Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients with Soft Tissue Sarcoma, Bone Sarcoma, or Colorectal Cancer Metastatic to the Lungs
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Erlotinib, Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Basal-Like Pancreatic Cancer, PANGEA Trial
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Gemcitabine and Leflunomide in Patients with Advanced Unresectable Pancreatic Cancer
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Gemcitabine, Cisplatin, and Nab-Paclitaxel in Combination with Tumor Treatment Fields for the Treatment of Recurrent and/or Metastatic Pancreatic Cancer
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Bosentan with Nab-Paclitaxel and Gemcitabine for the Treatment of Unresectable Pancreatic Cancer
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Fostamatinib in Combination with Gemcitabine and Nab-paclitaxel before and after Surgery for the Treatment of Resectable Pancreatic Cancer
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California
ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Chemoimmunotherapy Combined with Deep Hyperthermia and Spatially-fractionated Radiotherapy for the Treatment of Advanced Biliary Tract Cancer
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination with Gemcitabine, Cisplatin and Durvalumab for the Treatment of Biliary Tract Cancer Patients with Peritoneal Metastases
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Toripalimab, Gemcitabine, and Docetaxel before Chemoradiation for the Treatment of Locoregionally Advanced EBV Positive Nasopharyngeal Cancer
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
Status: Active
Location: See ClinicalTrials.gov
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Status: Active
Location: 3 locations
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Status: Active
Location: See ClinicalTrials.gov
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
Status: Active
Location: Nationwide Children's Hospital, Columbus, Ohio
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination
Status: Active
Location: See ClinicalTrials.gov
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
Status: Active
Location: See ClinicalTrials.gov
Risk-Adapted, Proteomic-Guided (PROphet CB, and CARG-TT) Systemic Therapy for the Treatment of Previously Untreated Unresectable or Metastatic Non-small Cell Lung Cancer
Status: Approved
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California